OptimalDosages.com publishes reference material for laboratory and educational use. Nothing here is medical advice, a prescription, or a recommendation for human administration.
By continuing you confirm you are 21 or older and that you are accessing this material in a research or educational capacity.
How the numbers on this site were put together, how we grade the evidence behind them, and what we will not do with them.
We think you should know exactly how this was built, because it changes how much weight the figures deserve.
The dose ranges and the citations were assembled by an AI system from its training knowledge of the published peptide literature. They were not compiled by researching each compound one at a time, and the individual citations have not been checked against the source records. Author names, journals and years may contain errors.
That is also why every reference on this site links to a PubMed search rather than a specific article ID. A search will take you to the real record if the paper exists. A fabricated ID would look authoritative and lead nowhere, which is worse than no link at all.
Three parts of the site do not come from that process:
What this means in practice: treat the ranges as a well-informed starting point for your own reading, not as a verified bibliography. Follow the links. If a number matters to a decision you are making, check it at the source.
Every compound carries an evidence tier, and we would rather show you a weak one honestly than dress it up:
| Tier | What it means |
|---|---|
| Clinical | Human trial or approved-label dosing has been published for this compound. |
| Preclinical | Laboratory and animal data only. No human dosing trials. |
| Limited | Sparse evidence, often from a single research programme, or figures reported only within the research community. |
Week-by-week schedules carry their own label so you can see where each one originated — a published label, a clinical trial protocol, a commonly used protocol, one we built from a compound's own cited range, or an OptimalDosages protocol anchored to a target we chose. Where no source publishes a schedule, the page says so rather than implying one exists.
A literature check runs weekly against Europe PMC, rotating through the catalogue so every compound is reviewed roughly monthly. It flags new human trials, dose findings, safety signals and retractions of papers we cite. It reports only — it cannot edit the site.
If you find an error, tell us and we will fix it. Corrections to dose figures or evidence tiers are made in place, and the build identifier in the footer changes whenever the site does, so you can tell whether you are looking at a current version.